Centanafadine: new US ADHD drug, and what it means in the UK

A new ADHD medication has made headlines after gaining approval in the United States. Centanafadine, sold under the brand name Simtriyo, has been described as a first-in-class treatment. But headlines about a "new ADHD drug" can easily be misread as meaning it is now available in the UK. It is not. This article sets out exactly what has happened, what it means, and what has not changed for anyone prescribed ADHD medication in England, Scotland, Wales or Northern Ireland.

What has actually been approved, and where

According to a press release from Otsuka dated 24 July 2026, the US Food and Drug Administration (FDA) approved Simtriyo (centanafadine), a once daily extended release capsule, for the treatment of ADHD in adults and in paediatric patients aged 6 and over weighing at least 20kg.

Otsuka describes centanafadine as a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor, meaning it works on three brain chemical systems rather than the two (dopamine and norepinephrine) targeted by most existing ADHD medicines. The company states that the FDA approval was supported by four pivotal Phase 3 clinical trials.

Crucially, this is a US regulatory decision only. It says nothing about UK availability. Otsuka's own release notes that commercial availability in the US still awaits DEA scheduling, because centanafadine is expected to be classified as a controlled substance, a separate US regulatory step that takes additional time even after FDA approval.

Is centanafadine available in the UK?

No. A search of the MHRA's licensed medicines database for "centanafadine" returns no authorised UK product, indicating there is currently no UK marketing authorisation for this medicine. This means that, as things stand, no doctor in the UK can lawfully prescribe centanafadine, regardless of what has happened in the US.

It is worth being clear about what UK licensing actually involves, because the process is genuinely separate from the American one:

• The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for assessing whether a medicine is safe, effective and of suitable quality to be licensed for use in Great Britain.
• An FDA approval in the US does not automatically transfer to the UK. A manufacturer must make a separate application to the MHRA, submitting clinical trial data for assessment.
• Even after a UK marketing authorisation is granted, NICE would typically need to assess the medicine before it could be routinely recommended and funded on the NHS in England and Wales, through its own appraisal process.
• Scotland has its own health technology assessment body, the Scottish Medicines Consortium, which conducts a parallel and separate process.

None of these UK-specific steps have happened for centanafadine at the time of writing. There is no confirmed timeline for a UK application, let alone a decision, and it would not be accurate to describe any UK launch date, because none exists.

What the underlying research shows

Separately from the regulatory story, centanafadine has been studied in clinical trials for some years. Peer-reviewed Phase 3 results in adults were published in May 2022, examining the medicine's effects in adults with ADHD. A more recent systematic review and meta-analysis of randomised controlled trials of centanafadine in ADHD has also pooled data across multiple trials.

This coaching site is not in a position to interpret or compare efficacy findings between centanafadine and other medicines, and we are not going to attempt that here. Efficacy and safety judgements are for regulators, prescribers and the clinical literature, not for a non-clinical article. Readers who want to understand what the trial data shows should read the published papers directly or discuss them with a healthcare professional, since interpreting clinical trial statistics correctly requires clinical training.

What this means if you are currently on ADHD medication in the UK

If you take methylphenidate, lisdexamfetamine, dexamfetamine, atomoxetine or guanfacine, this news does not change your current treatment or your options. NICE guideline NG87 continues to recommend lisdexamfetamine or methylphenidate as first-line pharmacological treatment for adults with ADHD in England and Wales, and this remains the standard your prescriber will be working from.

If you have questions about whether a different medication might suit you better, whether current side effects are worth raising, or whether new research changes anything about your own care, the right person to speak to is your GP or the specialist who prescribes your medication. This article cannot and does not offer that advice, and no non-clinical source should attempt to.

Why "new drug approved" stories need careful reading

Health and ADHD social media accounts often share US approval news as though it applies globally. It is easy to see why: the coverage is genuinely interesting, and there is understandable hope among people who have struggled to find a medication that works well for them or who experience side effects with current options. But conflating "approved somewhere" with "available here" can lead to disappointment, wasted time asking a GP about something not yet licensed, or worse, attempts to source unlicensed medication from abroad, which carries its own risks and is not something we would ever suggest.

The honest, currently verifiable position is:

• Centanafadine (Simtriyo) has FDA approval in the United States, announced 24 July 2026.
• It has no UK marketing authorisation, and does not appear on the MHRA's product register.
• There is no confirmed UK application, review timeline or launch date.
• NICE NG87 continues to guide first-line pharmacological treatment for adults with ADHD in England and Wales, unchanged by this news.

Where to go for reliable information

If you want to track whether centanafadine's UK status changes in future, the MHRA's licensed medicines search is the primary public source, and it will show a UK product record if and when a marketing authorisation is granted. NICE's website is the place to check for any future technology appraisal.

For any question about your own medication, diagnosis or care, please speak to your GP, psychiatrist or ADHD specialist. ADHD Tribe offers non-clinical coaching to help with the day-to-day practicalities of living with ADHD, such as organisation, routines and executive function strategies. We do not diagnose, prescribe or advise on medication, and nothing in this article is a substitute for medical care.

What to do if you read about centanafadine and want to know more

If a friend, a social media post or a news article has mentioned centanafadine and you are wondering whether it is relevant to you, the most useful first step is to check the two facts set out in this article: whether it has a UK marketing authorisation (at the time of writing, it does not) and whether NICE has published any guidance on it (it has not). Both can be checked directly using the MHRA's public product search and NICE's website, rather than relying on secondhand summaries of American news coverage.

What this means if you are unhappy with your current ADHD medication

News about a new medicine elsewhere can understandably prompt people to reflect on whether their current treatment is working well for them. If you are experiencing side effects, feel your current medication is not as effective as you would like, or simply want to understand what other licensed options exist in the UK, the right step is to raise this with your GP or specialist prescriber at a routine or requested review, rather than waiting for an unlicensed medicine to potentially become available at some unknown future date. NICE guideline NG87 sets out several licensed options already available in the UK, including different stimulant and non-stimulant medicines, and your prescriber is best placed to talk through whether an alternative, already-licensed option might suit you better.

References

• Otsuka: FDA approval update for centanafadine
• Phase 3 results of centanafadine in adults with ADHD, PubMed
• Systematic review and meta-analysis of centanafadine RCTs, PubMed
• MHRA licensed medicines search: centanafadine
• NICE NG87: ADHD diagnosis and management, recommendations

Understanding the US drug approval process, briefly

It can help to understand roughly why a US approval takes the shape it does, so the current UK gap makes more sense. The FDA approval process, which led to the 24 July 2026 announcement, assesses evidence of safety and efficacy submitted by the manufacturer, in this case supported by four pivotal Phase 3 trials according to Otsuka. Approval is one part of a longer process before a medicine reaches patients: Otsuka's own statement notes that commercial availability in the US still awaits DEA scheduling, because centanafadine is expected to be classified as a controlled substance in the same way existing stimulant ADHD medicines are. That extra step exists precisely because of the misuse potential associated with medicines that affect these brain chemical systems, and it is a further reminder that "approved" and "available to be prescribed and dispensed" are not the same milestone, even within a single country's system.

What might happen next, and what we genuinely don't know

We do not have any confirmed information about whether or when Otsuka might apply for a UK marketing authorisation, and this article will not speculate about a timeline, because doing so would go beyond what has actually been verified. What we can say is what the general UK process would involve if such an application were made:

• A manufacturer would submit a full licensing application to the MHRA, including the same or similar clinical trial data used in the US application, for independent UK assessment.
• MHRA assessment of a new medicine typically takes many months, and there is no guarantee of a particular outcome or timescale.
• If a UK marketing authorisation were granted, NICE would likely still need to conduct its own technology appraisal before recommending routine NHS funding in England and Wales, a separate process with its own timeline.
• Scotland runs a parallel appraisal process through the Scottish Medicines Consortium, again separate from both the MHRA and NICE.

None of these steps has begun, as far as the verified sources available to us show, and it would be inaccurate and unhelpful to imply otherwise.

A note on reading pharmaceutical company press releases

Otsuka's press release is, naturally, written to present positive news about its own product, which is a normal feature of company communications following a regulatory approval. That does not make the factual content of an approval announcement untrue, the FDA approval itself is a matter of public record, but it is worth reading such releases with the awareness that they are not independent clinical guidance, and they are not written with a UK audience's regulatory situation in mind. Independent sources, such as the MHRA's own product register and NICE's guidance pages, remain the most reliable places to check UK-specific facts.